Combined Antibiotic,Steroid,and Moisturizer Therapy in Eczema Treatment: Balancing Short-Term Relief with Long-Term Risks

Abstract

Combined antibiotic–corticosteroid–moisturizer therapy, often referred to as the Aron Regimen has gained popularity for managing atopic dermatitis (AD). While this therapy has been shown in some studies to provide short-term improvement in symptoms, evidence for its long-term utility is limited, and its widespread use raises concerns about promoting antibiotic resistance and disrupting the skin microbiome. Studies suggest that topical antibiotics provide limited benefit for most eczema cases, with only modest or context-specific benefits reported in more severe or treatment-resistant situations. Importantly, current clinical guidelines do not recommend the routine use of topical antimicrobials in the absence of clear infection. This review contextualizes the Aron Regimen within current evidence and emphasizes a more cautious, limited role for antibiotic-containing therapies in AD.

Introduction

Atopic dermatitis (AD), commonly referred to as eczema, is a chronic inflammatory skin disease affecting up to 20% of children and 10% of adults worldwide. ¹ AD is characterized by a complex interplay of genetic and environmental factors that results in skin inflammation. This condition goes beyond physical discomfort, compromising one’s well-being as patients often experience dry skin, redness, itching, sleep disturbances, psychological distress, and limitations in daily activities. ¹ Despite its high prevalence and impact on quality of life, the optimal treatment for eczema flares remains debated, particularly regarding the use of topical antimicrobials.

AD management is designed to address the disease pathophysiology, which includes a defective skin barrier, immune dysregulation, and microbial dysbiosis. ¹ The defective skin barrier, caused by genetic or environmental factors, increases susceptibility to irritants and allergens, causing inflammation and often colonization by Staphylococcus aureus, including methicillin-resistant S. aureus, which is known to exacerbate eczema. ²

Among the various therapeutic approaches, the “Aron Regimen,” also described in the literature as compounded antibacterial, steroid, and moisturizer (CASM), has been reported to provide short-term relief from AD symptoms. ³ This therapy, developed by Dr Richard Aron, consists of a topical antibiotic, topical corticosteroid (TCS), and moisturizer, and is typically applied 5 to 7 times daily with a gradual reduction to once daily, guided by the degree of clinical improvement. ³ Since the corticosteroid is diluted in the compound, its lower potency may reduce the risk of side effects compared with conventional medium- or high-potency therapies. In clinical practice, the formulation is often referred to as “magic cream” because of how rapidly it can provide relief for patients. Available evidence suggests that such a regimen may provide short-term improvement in select cases; however, its role remains uncertain and is not supported for routine use. Although this approach is increasingly considered outdated in contemporary dermatologic practice, dermatologists may still encounter patients initiated and maintained on this regimen by non-dermatologists. Therefore, the purpose of this review is to provide dermatologists with the context to critically appraise the available evidence, counsel patients, and support evidence-based alignment with current guidelines and antimicrobial stewardship principles.

Clinical Evidence on Antibiotic Use in AD

Observational studies in patients with AD have reported benefits from the Aron Regimen, consisting of compounded betamethasone valerate 0.1% cream (30-60 g), mupirocin 2% cream (22-44 g), and an emollient base (Vanicream™ or an equivalent; 250-500 g).^3,4 A retrospective case series of 116 patients (mean age 16.1 years) with variable AD severity, many of whom had previously failed mid- or high-potency TCS or systemic treatments, found the regimen to be effective at a follow-up visit around 49.5 days, which suggests it may be helpful for patients who have reached a therapeutic plateau with conventional therapies. ³ However, this case series prompted debate in the literature, as Harris and Fischer commented that frequent use of mupirocin is inconsistent with the principles of antibiotic stewardship, emphasizing that antibiotic–TCS therapy offers similar benefit as TCS alone. ⁵

Similarly, in a longitudinal survey of 728 patients (median age 7 years) with average patient-oriented eczema measure (POEM) scores characterized as moderate-to-severe, most patients reported substantial symptom improvement within 30 days of using the regimen, followed by a plateau in severity scores. ⁴ Despite survey responses being collected for up to 12 months, there was low retention at 1 year (19%), which limits conclusions about long-term outcomes. ⁴ Although these studies^3,4 briefly mention concerns about antibiotic resistance and suggest that alternatives or time-limited courses could reduce this risk, they do not provide empirical data on resistance patterns.

Randomized controlled trials (RCTs) offer mixed findings, especially regarding the additional value of antibiotics in non-severe cases. It should be noted that, unlike the Aron Regimen, most clinical trials and reviews of antibiotic–TCS therapy do not include a moisturizer; thus, their findings may not fully reflect outcomes with CASM. In a double-blind multicenter trial of 327 patients with eczema or AD, patients received hydrocortisone butyrate plus either mupirocin or a placebo ointment, applied 2 to 3 hours apart. ⁶ Both treatments led to improvement and were well-tolerated, with no significant difference in the global therapeutic effect between groups. In patients with more severe disease, combined antibiotic–TCS therapy provided a modest early benefit on day 7, but no differences were observed at later time points. ⁶

In a randomized double-blind pilot trial of 83 infants under 2 years of age with mild-to-moderate AD, researchers compared an emollient alone, hydrocortisone acetate alone, and hydrocortisone acetate combined with mupirocin. ⁷ At day 8, both steroid-containing regimens showed greater improvement than emollient alone. The combination therapy was associated with a statistically significant benefit in Eczema Area and Severity Index (EASI) scores at day 8 compared with hydrocortisone alone. However, Scoring Atopic Dermatitis (SCORAD) outcomes were similar between the steroid and combination groups, with no significant difference between them. ⁷

The CREAM study, a pragmatic RCT of 113 children with mild-to-moderate clinically infected eczema (often excluding severe infections), found that oral and topical antibiotics offered no clinically meaningful benefit compared to placebo and showed a trend toward slightly worse POEM and EASI scores at 2 weeks. ⁸ Although some participants may have concurrently used TCS, the study did not directly assess combination antibiotic–TCS therapy. Still, these results highlight the limited role of antibiotics in eczema flares in outpatient settings.

One prospective single-arm study followed 35 patients with moderate-to-severe AD who received a combined betamethasone valerate and fucidic acid cream. ⁹ Patients experienced improvements in disease severity and quality of life, with SCORAD scores decreasing and skin hydration increasing. However, the study revealed a marked rise in fucidic acid-resistant strains of S. aureus, from 8% at baseline to 58% post-treatment, ⁹ raising concerns about resistance with empirical topical antibiotic use for eczema.

Systematic reviews further illustrate the inconsistency in findings and highlight the overall low quality of available evidence. A Cochrane review by Birnie et al, including 1018 participants, found no clear evidence supporting the use of antimicrobials for AD, which they attributed to small and poorly reported studies. ¹⁰ This review was subsequently updated by George et al, who analyzed 1753 participants with mild-to-severe eczema and also found low-quality evidence, although they concluded that antibiotic–TCS combinations may produce small improvements in signs and symptoms compared to TCS alone. ¹¹ Overall, these reviews show that evidence remains insufficient to support the routine use of antibacterial treatments in standard eczema therapy.

The long-term implications of the CASM therapy are still largely unknown. Research so far has shed light on the formula’s immediate benefits but has left gaps in understanding its prolonged effects. The widespread use of antibiotics to combat bacterial colonization can inadvertently contribute to the rise of antibiotic resistance, which is a growing global concern. ¹² Sustained use has raised increasing concern about the emergence of mupirocin-resistant strains of S. aureus. ¹³ From an antimicrobial stewardship perspective, the routine or prolonged use of topical antibiotics for a chronic non-infectious condition such as AD represents unnecessary antibiotic exposure. Additionally, patients with AD are at risk of secondary infection, which highlights the importance of preserving the effectiveness of antimicrobial therapies for appropriate clinical indications. While antibiotics are appropriate in the setting of a clear secondary infection, their use in uncomplicated AD flares may accelerate the development of antibiotic resistance. Moreover, the disruption of the skin’s microbial balance through antibiotic use can potentiate S. aureus colonization, ¹⁴ creating a vicious cycle that further worsens eczema and results in increased antibiotic use.

Beyond antibiotic resistance, there are additional risks to consider when using topical antibiotics in children with AD. Mupirocin has been associated with potential effects on wound healing in experimental settings, although the clinical relevance remains uncertain. ¹⁵ Other adverse effects include allergic contact dermatitis and local irritation, which may complicate long-term management. ¹⁵ These findings support a cautious and limited role for antibiotic-containing regimens, particularly given the potential risks and the lack of evidence for sustained benefit.

In addition, it is important to consider current consensus guidelines, which do not recommend the use of topical antimicrobials for AD in the absence of overt infection. The Canadian Atopic Dermatitis Task Force developed a treatment algorithm, which includes the use of TCS and emollients, but not antimicrobial therapy. ¹⁶ The American Academy of Dermatology conditionally recommends against the use of topical antimicrobials for AD in both adults and children.^17,18 Similarly, the Joint Task Force on Practice Parameters recommends against the use of topical antimicrobials for uncontrolled AD unless there are clear clinical signs of serious bacterial skin infection, such as marked weeping, crusting, pustules, or evidence of systemic illness. ¹⁹ These guidelines support a shift away from routine use of antibiotic-containing regimens in AD, in keeping with de-implementation.

Conclusions and Future Directions

In conclusion, while some studies have reported short-term improvement with the CASM therapy in patients with eczema, the overall quality of evidence remains limited and is largely based on observational data. Existing clinical trials assessing long-term outcomes, most of which evaluated antibiotic–TCS therapy without the moisturizer component, have demonstrated modest or inconsistent benefits with uncertain clinical significance.

Importantly, current national and international guidelines, including those from the Canadian Atopic Dermatitis Task Force, the American Academy of Dermatology, and the Joint Task Force on Practice Parameters, do not support the routine use of topical antibiotics for AD in the absence of clear clinical infection.

Additionally, routine use of topical antibiotics carries risks, including antibiotic resistance and microbiome disruption, reinforcing the importance of antimicrobial stewardship. Further research should focus on independent longitudinal studies evaluating the long-term outcomes and comparing antibiotic-based regimens with non-antibiotic alternatives. Until such studies are available, the CASM therapy should be approached with caution and is not supported for routine and long term management of atopic dermatitis.